Prab: CSV import

2025-02-16T22:07:15Z

CSV import

← Older revision		Revision as of 22:07, 16 February 2025
Line 21:		Line 21:

	{{Chemotherapy-stub}}		{{Chemotherapy-stub}}

			== Evofosfamide ==
			<gallery>
			File:TH-302_Activation_and_Mechanism_of_action.png\|Activation and Mechanism of action
			</gallery>

Prab: CSV import

2024-03-22T07:15:33Z

CSV import

New page

'''Evofosfamide''' is a [[bioreductive prodrug]] that is specifically designed to be activated under hypoxic conditions, which are commonly found within solid tumors. Hypoxia, a condition characterized by an inadequate oxygen supply, is a hallmark of many cancers and contributes to both the aggressiveness of tumors and resistance to traditional therapies. By exploiting the unique environment of cancer cells, evofosfamide aims to improve the efficacy of cancer treatment while minimizing damage to healthy tissues.

==Mechanism of Action==
Evofosfamide, under its chemical designation TH-302, is activated in the absence of oxygen. Once inside the hypoxic zones of tumors, the prodrug is converted into its active form, a DNA alkylating agent, which causes DNA damage leading to cell death. This selective activation allows for targeted therapy against cancer cells while sparing normal, healthy cells that are typically well-oxygenated.

==Clinical Development==
Evofosfamide has been investigated in a variety of [[cancer]] types, including [[soft tissue sarcoma]], [[pancreatic cancer]], and [[non-small cell lung cancer]] (NSCLC). It has been studied in multiple phases of clinical trials, both as a monotherapy and in combination with other cancer treatments such as [[chemotherapy]] and [[radiotherapy]]. Despite showing promise in early-phase trials, evofosfamide has faced challenges in demonstrating a significant improvement in overall survival in phase III trials. For instance, the MAESTRO study, a phase III trial evaluating evofosfamide in combination with [[gemcitabine]] for the treatment of advanced pancreatic cancer, did not meet its primary endpoint of improved overall survival.

==Pharmacokinetics and Metabolism==
The pharmacokinetics of evofosfamide involves its distribution into hypoxic tissues and subsequent activation to its cytotoxic moiety. The metabolism of evofosfamide is primarily facilitated by reductive enzymes that are more active in hypoxic conditions. This activation process is crucial for the drug's selective toxicity towards hypoxic cancer cells.

==Adverse Effects==
The adverse effects associated with evofosfamide are similar to those observed with other chemotherapeutic agents, including [[nausea]], [[vomiting]], [[fatigue]], and [[myelosuppression]]. However, its targeted mechanism of action may reduce the severity of side effects compared to traditional chemotherapy, as it aims to spare healthy, oxygenated tissues.

==Future Directions==
The development of evofosfamide highlights the potential of targeting tumor hypoxia as a therapeutic strategy in oncology. Despite the setbacks in late-stage clinical trials, research continues to explore the optimal use of evofosfamide, including its combination with other therapeutic modalities and the identification of biomarkers to select patients most likely to benefit from this targeted approach.

[[Category:Cancer treatment]]
[[Category:Chemotherapy]]
[[Category:Prodrugs]]

{{Chemotherapy-stub}}

Evofosfamide - Revision history

Prab: CSV import

Prab: CSV import